The findings hint at why the ABYSS trial failed to show it was safe to stop beta-blockers after an MI in stable patients.

Background— Stroke is the second to third leading cause of death. Toll-like receptor 4 (TLR4) is a signaling receptor in innate immunity that is a specific immunologic response to systemic bacterial ...